Drug Trial Radar · NCT02057172
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Jan 2014
Primary completion
Oct 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Conditions
- Type 2 Diabetes
Interventions
HM11260CDrug
HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
liraglutideDrug
Liraglutide is a GLP-1 agonist.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeksTime frame: Up to 127 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanmi pharmaceutical
CA, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.